



*(Use as many sheets as necessary)*

Sheet	1	of	4
-------	---	----	---

Approved for use through 07/31/2008. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**Complete if Known**

Application Number	10/566,625
Filing Date	2 November 2006
First Named Inventor	Klaus, Stephen J.
Art Unit	1645
Examiner Name	Ogunbiyi, Oluwatosin A.
Attorney Docket Number	FP0617 US

## U. S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	MM-DD-YYYY			
/OO/	BA	WO 01/12784 - A1	02-22-2001	New England Med Ctr Hospital		

Examiner Signature	/Oluwatosin Ogunbiyi/	Date Considered	12/29/2008
-----------------------	-----------------------	--------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

*If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.*

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	10/566,625		
		Filing Date	2 November 2006		
		First Named Inventor	Klaus, Stephen J.		
		Art Unit	1645		
		Examiner Name	Ogunbiyi, Oluwatosin A.		
Sheet	2	of	4	Attorney Docket Number	FP0617 US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/OO/	CA	ARAVIND, L., ET AL., "The DNA-Repair Protein Alkb, EGL-9, and Lepreca Define New Families of 2-Oxoglutarate- and Iron-Dependent Dioxygenases" Genome Biol (2001) 2(3):1-8	
/OO/	CB	BRUICK, R.K., et al., "A Conserved Family of Prolyl-4-Hydroxylases That Modify HIF" Science (2001) 294(5545):1337-1340	
/OO/	CC	CONSTANTOULAKIS, P., et al., "Alpha-Amino-N-Butyric Acid Stimulates Fetal Hemoglobin in the Adult" Blood (1988) 72(6):1961-1967	
/OO/	CD	DUNCAN, T., et al., "Reversal of DNA Alkylation Damage by Two Human Dioxygenases" Proc Natl Acad Sci USA (2002) 99(26):16660-16665	
/OO/	CE	DUPUY, D., et al., "Mapping, Characterization, and Expression Analysis of the SM-20 Human Homologue, C1orf12, and Identification of a Novel Related Gene, SCAND2" Genomics (2000) 69(3):348-354	
/OO/	CF	EPSTEIN, A.C., et al., "C. Elegans Egl-9 And Mammalian Homologs Define a Family of Dioxygenases That Regulate HIF by Prolyl Hydroxylation" Cell (2001) 107(1):43-54	
/OO/	CG	FIBACH, E., et al., "Proliferation and Maturation of Human Erythroid Progenitors in Liquid Culture" Blood (1989) 73(1):100-103	
/OO/	CH	HEWITSON, K.S., et al., "Hypoxia-Inducible Factor (HIF) Asparagine Hydroxylase is Identical To Factor Inhibiting HIF (FIH) and is Related To The Cupin Structural Family" J Biol Chem (2002) 277(29):26351-26355	
/OO/	CI	HUANG, J., et al., "Sequence Determinants in Hypoxia-Inducible Factor-1alpha for Hydroxylation by the Prolyl Hydroxylases PHD1, PHD2, and PHD3" J Biol Chem (2002) 277(42):39792-39800	
/OO/	CJ	IVAN, M., et al., "HIF-Alpha Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O2 Sensing" Science (2001) 292(5516):464-468	

Examiner Signature	/Oluwatosin Ogunbiyi/	Date Considered	12/29/2008
--------------------	-----------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)	<b>Application Number</b>		10/566,625		
	<b>Filing Date</b>		2 November 2006		
	<b>First Named Inventor</b>		Klaus, Stephen J.		
	<b>Art Unit</b>		1645		
	<b>Examiner Name</b>		Ogunbiyi, Oluwatosin A.		
<b>Sheet</b>	3	of	4	<b>Attorney Docket Number</b>	FP0617 US

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/OO/	CK	JIA, S., et al., "A Fully Active Catalytic Domain of Bovine Aspartyl (Asparaginy) Beta-Hydroxylase Expressed in Escherichia Coli: Characterization and Evidence for the Identification of an Active-Site Region in Vertebrate Alpha-Ketoglutarate-Dependent Dioxygenases" Proc Natl Acad Sci USA (1994) 91(15):7227-7231	
/OO/	CL	JIANG, B.H., et al., "Transactivation and Inhibitory Domains of Hypoxia-Inducible Factor 1alpha Modulation of Transcriptional Activity by Oxygen Tension" J Biol Chem (1997) 272(31):19253-19260	
/OO/	CM	LANDO, D., et al., "FIH-1 is an Asparaginy Hydroxylase Enzyme That Regulates the Transcriptional Activity of Hypoxia-Inducible Factor" Genes Dev (2002) 16(12):1466-71	
/OO/	CN	LANDO, D., et al., "Asparagine Hydroxylation of the HIF Transactivation Domain a Hypoxic Switch" Science (2002) 295(5556):858-861	
/OO/	CO	LEDER, A., et al., "Butyric Acid, a Potent Inducer of Erythroid Differentiation in Cultured Erythroleukemic Cells" Cell (1975) 5(3):319-22	
/OO/	CP	LEY, T.J., et al., "5-Azacytidine Selectively Increases Gamma-Globin Synthesis in a Patient With Beta+ Thalassemia" N Engl J Med (1982) 307(24):1469-1475	
/OO/	CQ	MAHON, P.C., et al., "FIH-1: A Novel Protein That Interacts With HIF-1alpha and VHL To Mediate Repression of HIF-1 Transcriptional Activity" Genes Dev (2001) 15(20):2675-2686	
/OO/	CR	MCDONAGH, K.T., et al., "Hydroxyurea-Induced HbF Production in Anemic Primates: Augmentation by Erythropoietin, Hematopoietic Growth Factors, and Sodium Butyrate" Exp Hematol (1992) 20(10):1156-1164	
/OO/	CS	MYLLYHARJU, J., et al., "Characterization of the Iron- and 2-Oxoglutarate-Binding Sites of Human Prolyl 4-Hydroxylase" EMBO J (1997) 16(6):1173-1180	
/OO/	CT	NEWMARK, H.L., et al., "Butyrate as a Differentiating Agent: Pharmacokinetics, Analogues and Current Status" Cancer Lett (1994) 78(1-3):1-5	

<b>Examiner Signature</b>	/Oluwatosin Ogunbiyi/	<b>Date Considered</b>	12/29/2008
---------------------------	-----------------------	------------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/566,625
				Filing Date	2 November 2006
				First Named Inventor	Klaus, Stephen J.
				Art Unit	1645
				Examiner Name	Ogunbiyi, Oluwatosin A.
Sheet	4	of	4	Attorney Docket Number	FP0617 US

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>2</sup>
/OO/	CU	PERRINE, S.P., et al., "Butyric Acid Analogues Augment Gamma Globin Gene Expression in Neonatal Erythroid Progenitors" Biochem Biophys Res Commun (1987) 148(2):694-700		
/OO/	CV	PERRINE, S.P., et al., "Delay in the Fetal Globin Switch in Infants of Diabetic Mothers." N Engl J Med (1985) 312(6):334-338		
/OO/	CW	SRINIVAS, V., et al., "Characterization of an Oxygen/Redox-Dependent Degradation Domain of Hypoxia-Inducible Factor Alpha (HIF-Alpha) Proteins" Biochem Biophys Res Commun (1999) 260(2): 557-561		
/OO/	CX	TANIMOTO, K., et al., "Mechanism of Regulation of the Hypoxia-Inducible Factor-1 Alpha by the Von Hippel-Lindau Tumor Suppressor Protein" EMBO J (2000) 19(16):4298-4309		
/OO/	CY	TAYLOR, M.S., "Characterization and Comparative Analysis of the EGLN Gene Family" Gene (2001) 275(1):125-132		
/OO/	CZ	THORNBURG, L.D., et al., "A Non-Heme Iron Protein With Heme Tendencies: An Investigation of the Substrate Specificity of Thymine Hydroxylase" Biochem (1993) 32(50):14023-14033		
/OO/	DA	TORREALBA-DE RON, A.T., et al., "Perturbations in the Erythroid Marrow Progenitor Cell Pools May Play a Role in the Augmentation of Hbf by 5-Azacytidine" Blood (1984) 63(1):201-210		
/OO/	DB	WILSON, J.B., et al., "A New High-Performance Liquid Chromatographic Procedure for the Separation and Quantitation of Various Hemoglobin Variants in Adults and Newborn Babies" J Lab Clin Med (1983) 102(2):174-186		

Examiner Signature	/Oluwatosin Ogunbiyi/	Date Considered	12/29/2008
--------------------	-----------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.